ArticleFrontiers in immunology2026
Exploratory analysis of prognostic factors and hematologic dynamics in unresectable ESCC treated with concurrent versus interval immune checkpoint inhibitors combined with (chemo)radiotherapy: a multicenter real-world study.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Research Progress and Future Directions in Immune Cell Crosstalk in the Esophageal Cancer: A Bibliometric Analysis.Journal of inflammation research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The optimal integration of radiotherapy (RT) and immune checkpoint inhibitors (ICI) for esophageal squamous cell carcinoma (ESCC) remains undefined. This study aimed to evaluate treatment patterns, hematologic dynamics, and prognostic factors in patients receiving combined RT and ICI. Methods: We conducted a multicenter retrospective analysis of 426 patients with unresectable ESCC treated with RT and ICI, with and without chemotherapy. Survival outcomes were compared between concurrent and Interval (chemo)radiotherapy ((C)RT) and ICI strategies. Hematologic parameters, including lymphocyte counts and the systemic inflammation score (SIS), were dynamically assessed at baseline, during RT, and post-RT. Prognostic factors for overall survival (OS) and progression-free survival (PFS) were analyzed using univariate and multivariate Cox regression models. Results: Concurrent and Interval (C)RT-ICI strategies demonstrated comparable OS and PFS. Concurrent (C)RT-ICI was associated with a more pronounced decline in lymphocyte counts and a slightly higher incidence of adverse events, though generally manageable. Patients with isolated lymph node metastases achieved survival similar to those without metastasis and significantly better than those with organ metastases. During concurrent(C)RT-ICI, lymphocyte counts showed the most significant decline but gradually recovered 1-2 months after radiotherapy. Notably, SIS measured 1-2 months after RT emerged as a superior independent prognostic indicator for OS. Conclusions: In real-world practice, concurrent (C)RT-ICI is a safe and feasible treatment option for ESCC, though associated with greater lymphocyte suppression. During ICI treatment, SIS assessed after RT may serve as a simple and reliable prognostic biomarker. Patients with isolated nodal metastases appear to derive substantial benefit from (C)RT-ICI, warranting further validation in prospective randomized trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.